STALLERGENES AND ACTOGENIX TO DEVELOP AN INNOVATIVE NEW CLASS OF ORAL ALLERGY TREATMENTS



STALLERGENES exercised option to pursue the exclusive development of application
of ActoGeniX’s technology for targeted delivery of allergen-based treatments

Antony, France and Ghent, Belgium – 20 November 2014
 
STALLERGENES S.A. (Euronext Paris), a global healthcare company specialized in the
diagnosis and treatment of allergies through allergen immunotherapy-based solutions,
announced today that it has exercised the option to pursue the exclusive development of
an innovative new class of oral allergy treatments in partnership with ActoGeniX NV,
creator of ActoBioticsTM, in accordance with the contract signed in December 2013.
The collaboration centers on the development of a novel treatment approach based on
allergen-specific tolerance through innovative delivery of allergens expressed and
secreted by the allergen-secreting L.lactis bacteria. Stallergenes and ActoGeniX have
successfully conducted a Proof of Principle (PoP) study in preclinical models to validate
the application of ActoGeniX’s technology to allergens.
 
Dr. Bernard Coulie, Chief Executive Officer of ActoGeniX, said: “The PoP study
provides the scientific basis for the applicability of our technology platform in allergen
immunotherapy. We are extremely pleased to continue our collaboration with
Stallergenes while we focus on progressing our existing pipeline and validating our
technology platform in new therapeutic areas."
 
Dr. Philippe Moingeon, Senior Vice President, Research and Pharmaceutical
Development of STALLERGENES, said: “With this first study, we are confident that the
first-in-class technology platform provided by ActoGeniX is an innovative breakthrough
that can offer targeted delivery of allergen-based treatments and further increase the
efficacy of allergen immunotherapy. Our investment in such new technologies reflects
Stallergenes’ commitment to innovation.”
 
On December 2, 2013, STALLERGENES and ActoGeniX entered into an agreement for
the development of innovative first-in-class treatments of allergic diseases. Under the
terms of this agreement, ActoGeniX is responsible for the creation of clinical product
candidates based on the application of ActoBioticsTM genetically engineered lactic acid
bacteria to a set of allergens defined by Stallergenes. STALLERGENES will have full
development and exclusive worldwide commercialization rights to such clinical product
candidates, and ActoGeniX will be eligible to receive preclinical, clinical, regulatory and
commercial payments if certain milestones are reached, totaling up to € 75 million per
allergen, as well as tiered royalties on the future product’s net sales.
 
ABOUT ACTOGENIX
ActoGeniX is a biopharmaceutical company focused on the development and
commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals
for the targeted treatment of severe diseases with a high medical need. ActoBiotics™
represent a novel concept for oral administration of therapeutic proteins, and are
designed to be safer and more effective than injectable biopharmaceuticals.
ActoBiotics™ can deliver a wide range of therapeutic peptides and proteins, including
cytokines, enzymes, hormones and monoclonal antibodies.
 
ActoGeniX has confirmed the broad applicability of ActoBiotics™ and its proprietary
technology platform for a wide range of diseases, including oral, gastrointestinal,
metabolic, immune, and allergic diseases.
 
ActoGeniX was founded in 2006 as a spin-off from VIB and Ghent University. The
Company is headquartered in Ghent (Belgium) and employs 22 staff. ActoGeniX raised
46 million Euro (approximately 60 million US$) in 3 equity financing rounds from a
consortium of leading life sciences investors such as Gimv, Biotech Fund Flanders,
Baekeland Fund, Biovest, Saffelberg Investments (Belgium), Life Sciences Partners,
Aescap Venture (The Netherlands) and Ventech (France).
 
ActoGeniX has a strong and broad intellectual property position with a patent estate
encompassing more than 20 distinct patent families. With broad patent claims already
granted in major territories like the US, Europe, Japan, and China ActoGeniX is uniquely
positioned to successfully exploit the commercial potential of its promising ActoBiotics™.
www.actogenix.com
 
ABOUT STALLERGENES
STALLERGENES is a global healthcare company specialized in the diagnosis and
treatment of allergies. For more than 50 years, it has been expanding the existing
frontiers of science in order to provide allergy patients with more effective long-lasting
therapeutic options. Thanks to its innovation strategy, fuelled by investments amounting
to around 20% of total annual revenues as well as external partnerships,
STALLERGENES is able to provide targeted allergen immunotherapy-based allergy
solutions that significantly improve the lives of allergy patients around the world.
STALLERGENES operates in 21 countries and employs over 1,000 people. In 2013, the
Company generated total revenues of €248 million, and more than 500,000 patients were
treated with STALLERGENES products.
 
Euronext Paris (Compartment B)
CAC small
ISIN: FR0000065674
Reuters: GEN.PA
Bloomberg: GEN.FP
 
Additional information is available at http://www.stallergenes.com
 
Forward-looking statements related to Stallergenes
This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes’ management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forwardlooking statements whether as a result of new information or future events and except as required by law.
« back to overview
Follow us

STALLERGENES AND ACTOGENIX TO DEVELOP AN INNOVATIVE NEW CLASS OF ORAL ALLERGY TREATMENTS



STALLERGENES exercised option to pursue the exclusive development of application
of ActoGeniX’s technology for targeted delivery of allergen-based treatments

Antony, France and Ghent, Belgium – 20 November 2014
 
STALLERGENES S.A. (Euronext Paris), a global healthcare company specialized in the
diagnosis and treatment of allergies through allergen immunotherapy-based solutions,
announced today that it has exercised the option to pursue the exclusive development of
an innovative new class of oral allergy treatments in partnership with ActoGeniX NV,
creator of ActoBioticsTM, in accordance with the contract signed in December 2013.
The collaboration centers on the development of a novel treatment approach based on
allergen-specific tolerance through innovative delivery of allergens expressed and
secreted by the allergen-secreting L.lactis bacteria. Stallergenes and ActoGeniX have
successfully conducted a Proof of Principle (PoP) study in preclinical models to validate
the application of ActoGeniX’s technology to allergens.
 
Dr. Bernard Coulie, Chief Executive Officer of ActoGeniX, said: “The PoP study
provides the scientific basis for the applicability of our technology platform in allergen
immunotherapy. We are extremely pleased to continue our collaboration with
Stallergenes while we focus on progressing our existing pipeline and validating our
technology platform in new therapeutic areas."
 
Dr. Philippe Moingeon, Senior Vice President, Research and Pharmaceutical
Development of STALLERGENES, said: “With this first study, we are confident that the
first-in-class technology platform provided by ActoGeniX is an innovative breakthrough
that can offer targeted delivery of allergen-based treatments and further increase the
efficacy of allergen immunotherapy. Our investment in such new technologies reflects
Stallergenes’ commitment to innovation.”
 
On December 2, 2013, STALLERGENES and ActoGeniX entered into an agreement for
the development of innovative first-in-class treatments of allergic diseases. Under the
terms of this agreement, ActoGeniX is responsible for the creation of clinical product
candidates based on the application of ActoBioticsTM genetically engineered lactic acid
bacteria to a set of allergens defined by Stallergenes. STALLERGENES will have full
development and exclusive worldwide commercialization rights to such clinical product
candidates, and ActoGeniX will be eligible to receive preclinical, clinical, regulatory and
commercial payments if certain milestones are reached, totaling up to € 75 million per
allergen, as well as tiered royalties on the future product’s net sales.
 
ABOUT ACTOGENIX
ActoGeniX is a biopharmaceutical company focused on the development and
commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals
for the targeted treatment of severe diseases with a high medical need. ActoBiotics™
represent a novel concept for oral administration of therapeutic proteins, and are
designed to be safer and more effective than injectable biopharmaceuticals.
ActoBiotics™ can deliver a wide range of therapeutic peptides and proteins, including
cytokines, enzymes, hormones and monoclonal antibodies.
 
ActoGeniX has confirmed the broad applicability of ActoBiotics™ and its proprietary
technology platform for a wide range of diseases, including oral, gastrointestinal,
metabolic, immune, and allergic diseases.
 
ActoGeniX was founded in 2006 as a spin-off from VIB and Ghent University. The
Company is headquartered in Ghent (Belgium) and employs 22 staff. ActoGeniX raised
46 million Euro (approximately 60 million US$) in 3 equity financing rounds from a
consortium of leading life sciences investors such as Gimv, Biotech Fund Flanders,
Baekeland Fund, Biovest, Saffelberg Investments (Belgium), Life Sciences Partners,
Aescap Venture (The Netherlands) and Ventech (France).
 
ActoGeniX has a strong and broad intellectual property position with a patent estate
encompassing more than 20 distinct patent families. With broad patent claims already
granted in major territories like the US, Europe, Japan, and China ActoGeniX is uniquely
positioned to successfully exploit the commercial potential of its promising ActoBiotics™.
www.actogenix.com
 
ABOUT STALLERGENES
STALLERGENES is a global healthcare company specialized in the diagnosis and
treatment of allergies. For more than 50 years, it has been expanding the existing
frontiers of science in order to provide allergy patients with more effective long-lasting
therapeutic options. Thanks to its innovation strategy, fuelled by investments amounting
to around 20% of total annual revenues as well as external partnerships,
STALLERGENES is able to provide targeted allergen immunotherapy-based allergy
solutions that significantly improve the lives of allergy patients around the world.
STALLERGENES operates in 21 countries and employs over 1,000 people. In 2013, the
Company generated total revenues of €248 million, and more than 500,000 patients were
treated with STALLERGENES products.
 
Euronext Paris (Compartment B)
CAC small
ISIN: FR0000065674
Reuters: GEN.PA
Bloomberg: GEN.FP
 
Additional information is available at http://www.stallergenes.com
 
Forward-looking statements related to Stallergenes
This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes’ management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forwardlooking statements whether as a result of new information or future events and except as required by law.
« back to overview